Immunome directors bought shares, but the company's stock still fell despite the insider purchases.

Directors of Immunome Inc., a biotech firm developing cancer treatments, have recently bought shares in the company. Jean Jacques Bienaime purchased 7,000 shares, increasing his stake to 23,615 shares, while CTO Philip Tsai bought 12,300 shares, raising his ownership to 33,300 shares. Despite these insider purchases, Immunome's stock fell from $8.21 to $6.95 on March 25. The company is currently testing AL102 for desmoid tumor treatment and has several other cancer therapy candidates in development.